靶点- |
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
An Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral TTI-0102 (as a potential treatment for COVID-19) compared to Cystagon® in Healthy Adult Male and Female Volunteers
A Multi-center, Randomized, Double-blind, Placebo-controlled, Study to Assess the Safety, Tolerability, Pharmacodynamics (PD) and Efficacy of TTI-0102 for the Treatment of Patients With Mild to Moderate COVID-19
This is multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacodynamics (PD) and efficacy of TTI-0102 for the treatment of patients with mild to moderate COVID-19. This is a phase 2 study of cysteamine-pantetheine disulfide (TTI-0102), an antiviral, anti-infectious, antioxidant and anti-CRS (cytokine release syndrome) investigational drug. Subjects will be randomized 2:1 to receive TTI-0102 or placebo daily for up to 14 days. Up to 5 centers in the US and Canada will conduct this study. 60 patients will be enrolled.
100 项与 Thiogenesis Therapeutics, Inc. 相关的临床结果
0 项与 Thiogenesis Therapeutics, Inc. 相关的专利(医药)
100 项与 Thiogenesis Therapeutics, Inc. 相关的药物交易
100 项与 Thiogenesis Therapeutics, Inc. 相关的转化医学